Trial Profile

A Non-Comparative Open Pilot Trial to Assess the Safety and Pharmacokinetics of up to Three Single Doses of AERUMAB 11 (KBPA-101) in Patients With Hospital Acquired Pneumonia Caused by Serotype O11 P. Aeruginosa.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Panobacumab (Primary)
Indications Nosocomial pneumonia; Pseudomonal infections; Ventilator associated pneumonia
Focus Adverse reactions; Pharmacokinetics; Registrational
Sponsors Kenta Biotech

03 Jul 2012 Planned number of patients changed from 15 to 40 as reported by EudraCT.
15 Apr 2010 Results were presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases (Abstract No. 1126), according to a Kenta Biotech media release.
14 Sep 2009 Phase IIa data has been presented in a poster session at the 49th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), according to a Kenta Biotech media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com